Pharmacogenetic testing in the UK clinical setting

The Lancet

Volumn 381, Issue 9881, 2013, Pages 1903-

  Bartlett, Mark J ^a   Green, David W ^a   Shephard, Elizabeth A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19;

ANTICOAGULANT THERAPY; CURRICULUM; DECISION MAKING; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GENETIC SCREENING; GENOTYPE; HUMAN; LETTER; MEDICAL SCHOOL; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; POINT OF CARE TESTING; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL DEVELOPMENT; UNITED KINGDOM;

EID: 84878340887     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61160-5     Document Type: Letter

References (2)

1. Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012; 379: 1705-11.
2. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2012; 304: 1821-30.